Biodesix announces three abstracts to be presented at asco 2023 annual meeting

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 american society of clinical oncology (asco) annual meeting including a poster presented by friends of cancer research (focr) featuring genomic data contributed by biodesix and other organizations. this poster highlights long term patient outcomes from the ctmonit.
BDSX Ratings Summary
BDSX Quant Ranking